-- Nordion has entered into an agreement to divest its targeted therapies business to BTG, an international healthcare company based in London, for $200 million U.S. (154 million euros) in cash.To view the remainder of this article, and other exclusive ...
[Published Aunt Minnie - May 23 2013]